NCT02818907 (Pancreas-CGE) is a NA clinical trial of Additional biological samples in Pancreatic Cancer, sponsored by Centre Hospitalier Universitaire de Besancon.

Who is sponsoring NCT02818907?

NCT02818907 is sponsored by Centre Hospitalier Universitaire de Besancon.

What drugs are being tested in NCT02818907?

Interventions in NCT02818907: Additional biological samples.

What condition does NCT02818907 study?

NCT02818907 studies Pancreatic Cancer.

Is NCT02818907 still recruiting?

NCT02818907 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT02818907: Pancreas-CGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

Completed NA Last updated 19 September 2024

What this trial tests

NA trial testing Additional biological samples in Pancreatic Cancer in 290 participants. Completed in 7 July 2023.

Timeline

19 May 2016

Primary endpoint
7 July 2023

7 July 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Besancon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	290
Start date	19 May 2016
Primary completion	7 July 2023
Estimated completion	7 July 2023
Sites	8 locations across France

Drugs / interventions tested

Additional biological samples

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to collect clinical, biological and quality of life data from patients with a borderline or resectable pancreatic cancer. It will collect information from the date of diagnosis along the therapeutic care of the patients, and a 3-years follow-up after the end of the treatment. The database will be updated at each patient's visit. Biological samples will include: tumor, and plasma. Epidemiological data will also be collected, whereas Quality of life will be assessed by the EORTC standard. The objectives of this database are to identify new biomarkers (genomic, immunologic, and epidemiologic) and promote high quality standard research protocol.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
Merz V, Mangiameli D, Zecchetto C, Quinzii A, et al · · 2022 · cited 5× · PMID 35599791 · DOI 10.3389/fsurg.2022.866173
CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, et al · · 2024 · cited 2× · PMID 38169969 · DOI 10.1080/2162402x.2023.2294563

Verify or expand the search:

Other trials of Additional biological samples

Trials testing the same drug.

NCT04836793 — COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2 · unknown
NCT04365322 — Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19) · unknown

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02818907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02818907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing